Cnbc
@cnbc·4.2M subscribers·16.1K videos
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
Posted
October 13, 2015
Views
2,546
Likes
4
Engagement
0.16%
October 13, 2015
2,546
4
0.16%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
Biotech has been under fire lately. Few stocks have felt the sting more than BioMarin. Should you be buying the orphan drug maker after its decline?
» Subscribe to CNBC
» Watch more Mad Money here
» Read more about BioMarin here
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news
Watch full episodes
Follow Mad Money on Twitter
Like Mad Money on Facebook
Follow Cramer on Twitter
Connect with CNBC News Online!
Visit CNBC.com
Find CNBC News on Facebook
Follow CNBC News on Twitter
Follow CNBC News on Google+
Follow CNBC News on Instagram
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
